Table 3.
Compound | Fold increase of
EC50 versus wild-type virus
|
|||||
---|---|---|---|---|---|---|
Wild type* | 184-Ile | 184-Val | 188-His | 184-Ile + 188-His | 184-Val + 188-His | |
Nevirapine | 1 (0.03) | 0.67 | 2.3 | 1.7 | 28 | 6.7 |
BHAP U-90152 | 1 (0.006) | 1.0 | 0.50 | 10 | 167 | 83 |
Pyridinone L-697661 | 1 (0.017) | 0.76 | 0.41 | — | 58 | 2.9 |
TSAO-m3T | 1 (0.021) | 1.2 | 0.71 | 71 | 381 | 38 |
9-chloro-TIBO | 1 (0.02) | 1.0 | 0.50 | 45 | — | — |
α-APA | 1 (0.005) | 2.8 | 0.80 | 100 | 960 | 70 |
MKC-442 | 1 (0.002) | 1.0 | 1.0 | — | 390 | 25 |
UC-10 | 1 (0.029) | 0.30 | 0.28 | 6.9 | 7.9 | 2.7 |
UC-781 | 1 (0.002) | — | — | 8.0 | 37 | 8.0 |
HBY 097 | 1 (0.001) | 1.0 | 3.0 | 2.0 | 19 | 5.0 |
AZT | 1 (0.001) | 1.7 | 1.0 | 1.3 | 1.2 | 1.5 |
ddI | 1 (0.92) | 2.8 | 2.6 | 0.49 | 1.3 | 1.3 |
3TC | 1 (0.01) | 70 | ≥5,000 | 0.60 | 280 | >2,000 |
Values in parentheses represent the 50% effective concentration (EC50) values of the drugs for wild-type HIV-1/IIIB (in μg/ml). ddI, dideoxyinosine.